

Special Issue

The Role of Viruses in the Development of Cancer

Message from the Guest Editor

Viruses have been studied as etiological agents in the development of animal and human cancers for more than a century. This work has aided the identification of oncogenes and tumour suppressor genes as well as highlighting viruses that play a crucial role in the development of human cancers, for example, the role of HPVs in ano-genital and oral cancers, and of the HTLV 1 in ATL. The field continues to be buoyant, with new tumour viruses such as the DNA viruses, MCPyV and KSHV or HHV8 being discovered using DNA sequence and genomic analysis within the past two decades. While effective prophylactic vaccines have been developed against HPVs and HBV, there is still a requirement for novel therapeutic approaches to human cancers that are driven by tumour virus infection. Original research articles and reviews are welcome in this SI. Research areas may include fundamental studies on the molecular mechanisms of cell transformation and oncogenesis by DNA and RNA tumour viruses; the immune response to tumour viruses; the immune evasion of cancers driven by tumour viruses; prophylactic and therapeutic vaccines against tumour viruses and the cancers that they cause, etc.

Guest Editor

Prof. Dr. George Eric Blair
School of Molecular and Cellular Biology, University of Leeds, Leeds,
UK

Deadline for manuscript submissions

closed (31 March 2026)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/200751

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)